Posted by Michael Wonder on 22 May 2025
Tagrisso approved (with conditions) in Canada for patients with unresectable, stage III EGFR-mutated non-small cell lung cancer
21 May 2025 - Based on LAURA Phase 3 trial results which showed patients who took Targrisso after CRT had a median progression-free survival of more than 3 years.
Health Canada has granted a Notice of Compliance with conditions for Tagrisso (osimertinib) for the treatment of patients with locally advanced, unresectable (stage III) non-small cell lung cancer whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during or following platinum based chemoradiation therapy
